The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)
Not Applicable
Completed
- Conditions
- Phenylketonuria
- Registration Number
- NCT00892554
- Lead Sponsor
- Emory University
- Brief Summary
The purpose of this study is to determine if taking supplemental DHA improves measures of processing speed and executive function in teen and adult women with PKU.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 33
Inclusion Criteria
- Females
- Phenylketonuria
- Ages 12 years and older
- Able to complete neuropsychological testing
Exclusion Criteria
- Pregnancy
- Currently taking DHA supplement
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Cognitive processing speed 0 months, 4.5 months Executive function 0 months, 4.5 months
- Secondary Outcome Measures
Name Time Method Plasma and red blood cell DHA concentrations 0 months, 4.5 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link DHA supplementation to improved processing speed in PKU patients?
How does DHA supplementation compare to standard PKU dietary management for executive function outcomes?
Which biomarkers correlate with neurocognitive response to DHA in adult female PKU populations?
What adverse events are associated with long-term DHA supplementation in PKU patients?
Are there combination therapies with DHA showing enhanced neuroprotection in PKU-related cognitive deficits?
Trial Locations
- Locations (1)
Emory University
🇺🇸Atlanta, Georgia, United States
Emory University🇺🇸Atlanta, Georgia, United States